RSV cases are on the rise, surpassing both flu and COVID-19, and the medical community is sounding the alarm. This surge in respiratory syncytial virus (RSV) infections is not just a blip but a significant shift, as it marks the first time in five years that RSV cases have outpaced those of influenza and COVID-19. This trend is particularly concerning given the lack of awareness surrounding RSV, which, according to GP and Immunisation Coalition Chair Dr. Rodney Pearce, is a major driver of the soaring cases. The situation is further complicated by the out-of-pocket costs for those outside the eligible cohort to receive the free vaccine, which is a critical barrier to widespread protection.
The Immunisation Foundation of Australia (IFA) mid-winter report card paints a stark picture. As of the first half of 2026, RSV has been recorded in 83,678 cases, COVID-19 in 51,655 cases, and influenza in 49,785 cases. This represents a 25% increase in RSV notifications compared to the same period last year, with RSV now accounting for 45% of all respiratory virus notifications. The IFA predicts that this winter will see more than 127,000 RSV cases, a significant jump from the 37,000 cases recorded since the start of winter, which equates to nearly 900 cases per day.
Children under five years old are particularly vulnerable, accounting for 46% of confirmed RSV cases. The IFA's report also highlights a significant immunisation gap, with only 722,530 people aged 75 and over having received the free RSV vaccine, compared to 1.76 million who have had their flu shot. This means around one million over 75s are missing out on protection from the highly contagious virus. Moreover, around 64% of this older cohort were unaware that the RSV and influenza vaccines can be administered simultaneously, which may be contributing to lower RSV vaccination uptake.
The infant RSV immunisation program, on the other hand, has been a success story. It has led to a reduction in hospital admissions for newborns by almost half in its first year and has protected more than 360,000 babies since the national program began in early 2025. Dr. Pearce points out that the availability of the RSV vaccine has transformed the management of the virus, from a disease that couldn't be treated to one that is now being actively monitored and managed.
However, the program faces challenges, including vaccine shortages and the lack of awareness among both healthcare professionals and patients. Dr. Pearce notes that some states are rationing the vaccine, leading to a demand that is not being met. He also emphasizes the importance of GPs in raising awareness about RSV and vaccine eligibility, as the virus is moving from a disease that couldn't be treated to one that is now being actively managed and controlled.
In conclusion, the rise in RSV cases is a wake-up call that highlights the need for better awareness and access to the RSV vaccine. The medical community must work to address the barriers to vaccination, including the cost and the lack of awareness, to ensure that the vulnerable populations, especially children and the elderly, are protected from this highly contagious virus.
